Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.
Chung CH, Li J, Steuer CE, Bhateja P, Johnson M, Masannat J, Poole MI, Song F, Hernandez-Prera JC, Molina H, Wenig BM, Kumar S, Kuperwasser C, Stephens PJ, Farinhas JM, Shin DM, Kish JA, Muzaffar J, Kirtane K, Rocco JW, Schell MJ, Saba NF, Bonomi M. Chung CH, et al. Among authors: bhateja p. Clin Cancer Res. 2022 Jun 1;28(11):2329-2338. doi: 10.1158/1078-0432.CCR-21-3849. Clin Cancer Res. 2022. PMID: 35344035 Free PMC article. Clinical Trial.
A predictive survival model for patients with head and neck squamous cell carcinoma treated with immune check point inhibitors.
Bonomi M, Bhateja P, Issa M, Klamer B, Pan X, Blakaj A, Karivedu V, Mousa L, Mitchell D, Gamez M, Kang S, Seim NB, Old M, Carrau R, Rocco J, Blakaj D. Bonomi M, et al. Among authors: bhateja p. Oral Oncol. 2020 Nov;110:104900. doi: 10.1016/j.oraloncology.2020.104900. Epub 2020 Jul 20. Oral Oncol. 2020. PMID: 32702630 Free article.
Identification of Clinical and Socioeconomic Predictors of Adjuvant Therapy after Trans-Oral Robotic Surgery in Patients with Oropharyngeal Squamous Cell Carcinoma.
Baliga S, Klamer B, Jhawar S, Gamez M, Mitchell D, Blakaj A, Grecula J, Gardner U, Dibs K, Old M, Seim N, Kang S, Carrau R, Agrawal A, Karivedu V, Bhateja P, Ozer E, Rocco J, Bonomi M, Blakaj D. Baliga S, et al. Among authors: bhateja p. Cancers (Basel). 2020 Sep 1;12(9):2474. doi: 10.3390/cancers12092474. Cancers (Basel). 2020. PMID: 32882857 Free PMC article.
Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study.
Chung CH, Bonomi M, Steuer CE, Li J, Bhateja P, Johnson M, Masannat J, Song F, Hernandez-Prera JC, Wenig BM, Molina H, Farinhas JM, McMullen CP, Wadsworth JT, Patel KB, Kish JA, Muzaffar J, Kirtane K, Rocco JW, Schell MJ, Saba NF. Chung CH, et al. Among authors: bhateja p. Cancers (Basel). 2021 Mar 9;13(5):1180. doi: 10.3390/cancers13051180. Cancers (Basel). 2021. PMID: 33803335 Free PMC article.
Treatment Outcomes of Head and Neck Cancer Patients in the Elderly Receiving Different Chemoradiation Combinations: A Single-Center Experience.
Karivedu V, Bonomi M, Issa M, Blakaj A, Klamer BG, Pan X, Old M, Bhateja P, Kang S, Seim N, Ozer E, Agrawal A, Mitchell D, Gamez ME, Grecula J, Jhawar SR, Baliga S, Carrau RL, Rocco J, Blakaj D. Karivedu V, et al. Among authors: bhateja p. Oncol Res Treat. 2021;44(10):521-529. doi: 10.1159/000518548. Epub 2021 Aug 17. Oncol Res Treat. 2021. PMID: 34515190 Free article.
T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma.
Wang X, Muzaffar J, Kirtane K, Song F, Johnson M, Schell MJ, Li J, Yoder SJ, Conejo-Garcia JR, Guevara-Patino JA, Bonomi M, Bhateja P, Rocco JW, Steuer CE, Saba NF, Chung CH. Wang X, et al. Among authors: bhateja p. J Immunother Cancer. 2022 Jun;10(6):e004512. doi: 10.1136/jitc-2022-004512. J Immunother Cancer. 2022. PMID: 35676062 Free PMC article.
Update of a prognostic survival model in head and neck squamous cell carcinoma patients treated with immune checkpoint inhibitors using an expansion cohort.
Issa M, Klamer BG, Mladkova N, Laliotis GI, Karivedu V, Bhateja P, Byington C, Dibs K, Pan X, Chakravarti A, Grecula J, Jhawar SR, Mitchell D, Baliga S, Old M, Carrau RL, Rocco JW, Blakaj DM, Bonomi M. Issa M, et al. Among authors: bhateja p. BMC Cancer. 2022 Jul 14;22(1):767. doi: 10.1186/s12885-022-09809-5. BMC Cancer. 2022. PMID: 35836204 Free PMC article.
Association between Tumor Microbiome and Hypoxia across Anatomic Subsites of Head and Neck Cancers.
Dhakal A, Upadhyay R, Wheeler C, Hoyd R, Karivedu V, Gamez ME, Valentin S, Vanputten M, Bhateja P, Bonomi M, Konieczkowski DJ, Baliga S, Mitchell DL, Grecula JC, Blakaj DM, Denko NC, Jhawar SR, Spakowicz D. Dhakal A, et al. Among authors: bhateja p. Int J Mol Sci. 2022 Dec 8;23(24):15531. doi: 10.3390/ijms232415531. Int J Mol Sci. 2022. PMID: 36555172 Free PMC article.
Patient-reported outcomes in immunotherapy for head and neck cancer.
Kirtane K, Hoogland AI, Li X, Rodriguez Y, Scheel K, Small BJ, Oswald LB, Muzaffar J, Kish JA, Bonomi M, Bhateja P, Saba NF, Steuer CE, Chung CH, Jim HSL. Kirtane K, et al. Among authors: bhateja p. Head Neck. 2023 Jul;45(7):1761-1771. doi: 10.1002/hed.27388. Epub 2023 May 4. Head Neck. 2023. PMID: 37141438
48 results